The Diagnostic Value of Systemic Immune-Inflammatory Index (SII) and Lymphocyte–Albumin–Neutrophil Ratio (LANR) in Chronic Obstructive Pulmonary Disease with Lung Cancer
DOI: https://doi.org/10.2147/jir.s474263
IF: 4.5
2024-08-21
Journal of Inflammation Research
Abstract:Yidan Xu, 1, &ast Lu Zhang, 1, &ast Zhiyang Chen, 1 Xiaonan Sun, 1 Mengdan Zhao, 1 Qirui Wu, 2 Jiqing Hao 1 1 Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China; 2 Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou, Fujian, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jiqing Hao, Department of Oncology, The First Affiliated Hospital of Anhui Medical University, 81 Meishan Road, Hefei, Anhui, People's Republic of China, Tel +86-13965029739, Email Purpose: This study aims to explore the association of inflammatory markers such as the Systemic Immune-Inflammatory Index (SII) and LANR with the comorbidity of Chronic Obstructive Pulmonary Disease (COPD) and lung cancer. Patients and Methods: A cross-sectional analysis was conducted on the clinical data of 309 patients with COPD only and 193 patients with COPD and lung cancer who attended the First Affiliated Hospital of Anhui Medical University. Additionally, we examined autonomous risk factors that contribute to the simultaneous development of COPD and lung cancer through univariate and multivariate logistic regression analyses. This analysis resulted in the development of a nomogram model for visual representation. The effectiveness of the model was assessed using a receiver operating characteristic (ROC) curve, calibration curve, and clinical decision analysis (DCA) curve, with internal validation conducted via repeated sampling methods. Results: Multivariate analysis of clinical characteristics and inflammatory markers showed that smoking history of > 60 pack-years, hemoptysis, emphysema, WBC count > 5.53 (× 10^9/L), SII > 629.285, and LANR < 11.39 were significantly associated with the comorbidity of COPD and lung cancer. These factors were subsequently integrated into the nomogram model. The AUC of the model stood at 0.849 (95% CI: 0.815– 0.882), demonstrating a notable improvement over the COPD-LUCSS scoring system (AUC: 0.716, 95% CI: 0.671– 0.761). The DCA curve indicated a notable clinical advantage provided by the model. Additionally, patients with stage IV tumors exhibited elevated SII levels and reduced LANR levels compared to earlier stages, indicating potential prognostic significance for both markers. Conclusion: Increased levels of the inflammatory markers SII and LANR are associated with the risk of comorbidity of COPD and lung cancer. Keywords: lung cancer, inflammation, systemic immune-inflammation index, nomogram, LANR, chronic obstructive pulmonary disease Lung cancer is a type of malignancy that originates from respiratory epithelial cells located in the bronchi, bronchioles, and alveoli. It ranks among the top diseases globally in terms of both its incidence and mortality rates. The primary pathological subtypes of lung cancer encompass squamous cell carcinoma, adenocarcinoma, and small cell lung cancer. The development of lung cancer involves a complex pathogenesis, closely linked to chronic obstructive pulmonary disease (COPD). COPD is a chronic lung condition marked by persistent airflow limitation caused by ongoing inflammation of the airways, leading to obstructive bronchiolitis and emphysema. Due to demographic aging and environmental pollution, the incidence of COPD is on the rise. 1 Research findings indicate that the risk of lung cancer among COPD patients is significantly elevated, ranging from 4 to 6 times higher than in non-COPD. 2 This risk is notably linked to squamous cell carcinoma, as highlighted by recent studies. 3 Hence, it is of paramount importance to promptly identify high-risk individuals who exhibit an association between COPD and the progression of lung cancer. De-Torres et al 4 introduced the "COPD Lung Cancer Screening Score (COPD-LUCSS)" for COPD patient management, incorporating age, body mass index, smoking pack-years, and emphysema presence. However, multiple reports have highlighted its limited predictive efficacy. 5,6 For instance, in a study conducted by Gagnat among a community COPD population, 5 the COPD-LUCSS score exhibited a C-index of 0.63 and an area under the Receiver Operating Characteristic curve (ROC-AUC) of 0.61. Hence, it is essential to identify straightforward yet efficient biomarkers for COPD patients with lung cancer and create screening tools. The mechanisms underlying the advancement of COPD to lung cancer mainly include genetic susceptibility, oxidative stress-antioxidant imbalance, formation of a tumor-promoting inflammatory microenviron -Abstract Truncated-
immunology